Nasdaq exas.

Exact Sciences world-class team is the driving force behind the most innovative growth engine in cancer diagnostics. Our scientists are using advanced technologies to harness the power of DNA, RNA ...The Zacks Consensus Estimate for Exact Sciences’ third-quarter 2023 revenues is pegged at $614.6 million, suggesting a rise of 17.5% from the year-ago reported figure.Exact Sciences Corporation (NASDAQ:EXAS) Q2 2023 Earnings Call Transcript August 1, 2023 Exact Sciences Corporation beats earnings expectations. Reported EPS is $-0.45, expectations were $-0.51.... Back to EXAS Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following …Web

Exact Sciences (NASDAQ: EXAS) is a biotech stock leveraging AI. The company also comprises the largest holding in Cathie Wood’s ARK Genomic Revolution ETF (BATS: ARKG) at 10.38% total weight.

Analyst Price Forecast Suggests 9.61% Upside. As of April 24, 2023, the average one-year price target for Exact Sciences is 77.82. The forecasts range from a low of 55.55 to a high of $99.75. The ...MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its ...

EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission. Find the latest Financials data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com. Fintel reports that on October 10, 2023, Piper Sandler upgraded their outlook for Exact Sciences (NASDAQ:EXAS) from Neutral to Overweight. As of October 5, 2023, the average one-year price target ...Discover historical prices for EXAS stock on Yahoo Finance. View daily, weekly or monthly format back to when Exact Sciences Corporation stock was issued. Feb 7, 2023 · MADISON, Wis., Feb. 7, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS ), a leading provider of cancer screening and diagnostic tests, today announced the launch of the OncoExTra ... Find out the direct holders, institutional holders and mutual fund holders for Exact Sciences Corporation (EXAS).

Exact Sciences EXAS Operating Losses;.Another 70% to Fall!! The EXAC chart has been a downtrend from $130 to $40 with a High VOLUME. The stock is making new bottoms while insiders and the executive team have constantly been selling at any price! The stock is down 70% from its high of $137!

One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 0.09%, and its shares gained 105.65% of their value over the last 52 weeks. Exact Sciences Corporation (NASDAQ:EXAS) has a market ...

Fintel reports that on May 10, 2023, Craig-Hallum upgraded their outlook for Exact Sciences (NASDAQ:EXAS) from Hold to Buy.. Analyst Price Forecast Suggests 9.61% Upside. As of April 24, 2023, the ...Exact Sciences Corporation (EXAS) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 64.83 -0.23 (-0.35%) As of 12:06PM EST. Market …WebNov 25, 2023 · Exact Sciences (NASDAQ:EXAS) produces and sells diagnostic and cancer screening tests. The company is best known for its Cologuard product. That said, Exact Sciences has several other revenue ... Find the latest on option chains for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.Exact Sciences Corporation Common Stock ... Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day.The Zacks Consensus Estimate for Exact Sciences’ third-quarter 2023 revenues is pegged at $614.6 million, suggesting a rise of 17.5% from the year-ago reported figure.On May 17, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $78.63 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 18.54%, and its shares gained 45.61% of ...

Exact Sciences (EXAS) closed the most recent trading day at $60.68, moving -0.49% from the previous trading session. This change was narrower than the S&P 500's daily loss of 2.77%. Meanwhile, the ...May 15, 2023 · Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. The company is known for its flagship colon cancer ... Exact Sciences was founded in 1995 in Marlborough, Massachusetts, by Stanley Lapidus and Anthony Shuber as a company focused on the development of a non-invasive test for colorectal cancer. The company eventually went public with an initial offering on the NASDAQ in 2001. Exact Sciences (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, visits the Nasdaq MarketSite in Times Square. In honor of the occasion, Kevin Conroy, Chairman & CEO ...First on this list of millionaire-maker stocks is Exact Sciences (NASDAQ :EXAS ), an exciting company in the world of cancer research. Exact Sciences has developed one highly successful cancer ...

EXACT Sciences Corp. is a cancer screening and diagnostics company. The company is headquartered in Madison, Wisconsin and currently employs 6,420 full-time employees. The company went IPO on 2001-01-30. The firm provides a portfolio of products for earlier cancer detection. The company offers laboratory testing services from its Cologuard ...

First on this list of millionaire-maker stocks is Exact Sciences (NASDAQ :EXAS ), an exciting company in the world of cancer research. Exact Sciences has developed one highly successful cancer ...The intraday chart, the last-five real-time quotes and sales data. Real-time stock quotes can be used to help inform investors when researching potential investment opportunities. 2.68%. +0.25 0. ...At Stock Options Channel, our YieldBoost formula has looked up and down the EXAS options chain for the new August 26th contracts and identified one put and one call contract of particular interest ...20.11.23 NASDAQ Composite Index-Wert EXACT Sciences-Aktie: So viel Gewinn hätte eine EXACT Sciences-Investition von vor 10 Jahren eingebracht 06.11.23 …WebExact Sciences Corp. (NASDAQ: EXAS) is on a self-proclaimed mission to change the way cancer is detected and treated. The Madison, Wisconsin company is among the market’s best price performers ...Find the latest on short interest for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.This year, Exact Sciences (NASDAQ: EXAS) expects its revenue will total just under $2.1 billion. That means that in just five years, its top line will have grown by an incredible 683%.Exact Sciences Corporation Common Stock (EXAS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.WebEXAS U.S.: Nasdaq Exact Sciences Corp. Watch list NEW Set a price target alert Open Last Updated: Nov 20, 2023 2:33 p.m. EST Real time quote $ 67.73 1.43 2.15% Previous …WebNov 9, 2022 · EXACT Sciences Corporation (NASDAQ:EXAS) Number of Hedge Fund Holders: 28. Exact Sciences Corporation (NASDAQ:EXAS) is a leading global provider of cancer screening and diagnostic test products ...

Feb 16, 2021 · MADISON, Wis., Feb. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has entered into an agreement to acquire Ashion Analytics, LLC (Ashion) from The ...

In trading on Friday, shares of EXACT Sciences Corp. (Symbol: EXAS) crossed below their 200 day moving average of $46.11, changing hands as low as $45.88 per share. EXACT Sciences Corp. shares are ...

1 Mar 2017 ... Exact sciences rings the Nasdaq Closing Bell! $EXAS #CRCcountdown.Nov 9, 2022 · EXACT Sciences Corporation (NASDAQ:EXAS) Number of Hedge Fund Holders: 28. Exact Sciences Corporation (NASDAQ:EXAS) is a leading global provider of cancer screening and diagnostic test products ... Fintel reports that on May 10, 2023, Credit Suisse maintained coverage of Exact Sciences (NASDAQ:EXAS) with a Neutral recommendation.. Analyst Price Forecast Suggests 9.61% Upside. As of April 24 ...EXACT Sciences Corp. is a cancer screening and diagnostics company. The company is headquartered in Madison, Wisconsin and currently employs 6,420 full-time employees. The company went IPO on 2001-01-30. The firm provides a portfolio of products for earlier cancer detection. The company offers laboratory testing services from its Cologuard ...Exact Sciences Corporation (NASDAQ:EXAS) is an extremely timely and compelling short, with an imminent catalyst that we believe will cause shares to plummet as much as 75% in the near future. EXAS ...Exact Sciences (NASDAQ:EXAS) stands out as a key player in the field of cancer detection and diagnostics, attracting the attention of investors seeking innovative opportunities.Its recent ...In the past year, this Zacks Rank #3 (Hold) stock has gained 6.3% against a 9.1% decline of the industry and a 4.7% decline of the S&P 500 composite. The renowned global medical device company has ...EXACT SCIENCES CORP ( EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...Dec 1, 2023 · Exact Sciences Co. (NASDAQ:EXAS) announced its quarterly earnings results on Tuesday, August, 1st. The medical research company reported ($0.45) EPS for the quarter, beating analysts' consensus estimates of ($0.50) by $0.05. The medical research company earned $622.10 million during the quarter, compared to the consensus estimate of $601.14 ... Find the latest news headlines from Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.The latest price target for Exact Sciences ( NASDAQ: EXAS) was reported by Goldman Sachs on Friday, November 3, 2023. The analyst firm set a price target for 90.00 expecting EXAS to rise to within ... MADISON, Wis., Jan. 5, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has completed its previously announced acquisition of Thrive Earlier Detection Corp. ("Thrive").

Oct 8, 2023 · Exact Sciences (NASDAQ: EXAS) and Guardant Health make diagnostic tests to help screen for cancer. The two healthcare stocks have similar price-to-sales (P/S) ratios, and over the past five years ... Direct. 3,000. $16.52. 42,830. Back to EXAS Overview. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC ...Exact Sciences (NASDAQ:EXAS) is a leading international company specialized in advanced cancer diagnostics. Renowned for its development of impactful cancer diagnostic tests, ...Investing in Exact Sciences (NASDAQ:EXAS) a year ago would have delivered you a 59% gain. Exact Sciences Corporation ( NASDAQ:EXAS ) shareholders might be concerned after seeing the share price ...Instagram:https://instagram. nyse ftchnasdaq otlkdental plans in texasbest penny stocks for today The Investor Relations website contains information about Nasdaq, Inc.'s business for stockholders, potential investors, and financial analysts. pnnt stockbest malpractice insurance for np Exact Sciences EXAS continues to make significant progress with its Cologuard test. The integration of PreventionGenetics also buoys optimism. Escalating expenses, its sole reliance on Cologuard ... intc buy or sell Exact Sciences Corporation. Add. exactsciences.com · $EXASNASDAQ. $93.37. Exact Sciences Corporation provides cancer screening and diagnostic test products in ...Find the latest Financials data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.WebApr 27, 2022 3:33PM EDT. A mong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Qualcomm Inc (Symbol: QCOM), where a total of 80,465 ...